MCID: LRG014
MIFTS: 44

Large Cell Neuroendocrine Carcinoma

Categories: Cancer diseases, Neuronal diseases, Respiratory diseases

Aliases & Classifications for Large Cell Neuroendocrine Carcinoma

MalaCards integrated aliases for Large Cell Neuroendocrine Carcinoma:

Name: Large Cell Neuroendocrine Carcinoma 12 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050872
UMLS 70 C1265996

Summaries for Large Cell Neuroendocrine Carcinoma

Disease Ontology : 12 A lung large cell carcinoma that derives from neuroendocrine cells.

MalaCards based summary : Large Cell Neuroendocrine Carcinoma is related to pulmonary large cell neuroendocrine carcinoma and ovarian large-cell neuroendocrine carcinoma. An important gene associated with Large Cell Neuroendocrine Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Developmental Biology and CREB Pathway. The drugs Paclitaxel and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and cervix, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Large Cell Neuroendocrine Carcinoma

Diseases related to Large Cell Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 557)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 32.5 SYP NCAM1 CHGA ASCL1 ALK
2 ovarian large-cell neuroendocrine carcinoma 32.2 SYP NCAM1 KRT7 KRT20 ENO2 CHGA
3 adenoma 30.9 SYP KRT7 KRT20 CHGA
4 neuroendocrine carcinoma 30.8 SYP PDGFRA NKX2-1 NCAM1 KRT7 KRT20
5 carcinoid syndrome 30.8 SYP ENO2 CHGA
6 appendix adenocarcinoma 30.8 SYP KRT7 KRT20 CHGA
7 neuroendocrine tumor 30.7 SYP NKX2-1 NCAM1 KRT20 ENO2 CHGA
8 spindle cell sarcoma 30.7 NTRK3 KRT7 KIT
9 gallbladder adenocarcinoma 30.7 KRT20 ERBB2 EGFR
10 lung large cell carcinoma 30.6 SYP NTRK3 NKX2-1 NCAM1 CHGA
11 adenocarcinoma in situ 30.6 KRT7 KRT20 EGFR
12 papillary adenocarcinoma 30.5 NKX2-1 KRT7 ERBB2
13 cystitis cystica 30.5 KRT7 KRT20
14 ureteral benign neoplasm 30.5 SYP NKX2-1 KRT7
15 carcinosarcoma 30.5 KRT7 KIT ERBB2 EGFR
16 pulmonary blastoma 30.4 SYP NKX2-1 EGFR CHGA
17 keratinizing squamous cell carcinoma 30.3 SYP NKX2-1 KRT7 EGFR
18 suppression of tumorigenicity 12 30.3 SYP ERBB2 EGFR CHGA
19 lung cancer susceptibility 3 30.3 NKX2-1 KRT7 KRT20 ERBB2 EGFR ALK
20 cystadenoma 30.3 SYP KRT7 KRT20 CHGA
21 adenocarcinoma 30.3 NTRK3 NTRK2 NKX2-1 KRT7 KRT20 KIT
22 bronchiolo-alveolar adenocarcinoma 30.3 NKX2-1 KRT7 KRT20 EGFR
23 fibrous histiocytoma 30.2 KIT ENO2 ALK
24 thymoma 30.2 SYP NKX2-1 KIT EGFR CD274
25 fibrosarcoma 30.1 PDGFRA NTRK3 KIT ALK
26 basaloid squamous cell carcinoma 30.1 SYP KRT7 KRT20 ENO2 EGFR CHGA
27 oligodendroglioma 30.0 SYP PDGFRA NTRK2 ENO2 EGFR
28 tubular adenocarcinoma 30.0 SYP KRT7 KRT20 ERBB2 ENO2 EGFR
29 bile duct adenocarcinoma 30.0 KRT7 ERBB2 EGFR
30 cervical adenocarcinoma 30.0 KRT7 KRT20 ERBB2 EGFR
31 malignant astrocytoma 30.0 PDGFRA ERBB2 EGFR CHGA
32 papilloma 30.0 KRT7 KRT20 ERBB2 EGFR
33 colorectal adenocarcinoma 29.9 NKX2-1 KRT7 KRT20 KIT ERBB2 EGFR
34 transitional cell carcinoma 29.9 KRT7 KRT20 KRT18 ERBB2 ENO2 EGFR
35 mucinous adenocarcinoma 29.9 NKX2-1 KRT7 KRT20 KIT ERBB2 EGFR
36 teratoma 29.9 SYP NKX2-1 KRT7 KRT20 KRT18 KIT
37 uterine carcinosarcoma 29.8 KIT ERBB2 EGFR CD274
38 horseshoe kidney 29.7 SYP NKX2-1 KRT7 KRT20 ENO2 EGFR
39 papillary carcinoma 29.7 SYP NKX2-1 KRT7 KRT20 ERBB2 CHGA
40 adenosquamous carcinoma 29.7 SYP PDGFRA NKX2-1 KRT7 KRT18 KIT
41 lung benign neoplasm 29.7 SYP NKX2-1 NCAM1 KRT7 KRT20 ENO2
42 cystic teratoma 29.6 SYP NKX2-1 KRT7 KRT20 KRT18 KIT
43 pulmonary neuroendocrine tumor 29.6 SYP NKX2-1 NCAM1 ENO2 DLL3 CHGA
44 intrahepatic cholangiocarcinoma 29.6 KRT7 KRT20 ERBB2 EGFR CD274
45 breast neuroendocrine neoplasm 29.6 SYP NCAM1 KRT7 KRT20 ERBB2 ENO2
46 large cell carcinoma 29.6 SYP PDGFRA NTRK3 NKX2-1 NCAM1 KRT7
47 bile duct cancer 29.6 NCAM1 KRT7 ERBB2 EGFR CD274
48 pleomorphic carcinoma 29.4 NKX2-1 KRT7 KRT18 KIT EGFR CD274
49 gallbladder cancer 29.4 NCAM1 KRT7 KRT20 ERBB2 EGFR CD274
50 small cell cancer of the lung 29.4 SYP NKX2-1 NCAM1 KRT7 KRT20 KRT18

Graphical network of the top 20 diseases related to Large Cell Neuroendocrine Carcinoma:



Diseases related to Large Cell Neuroendocrine Carcinoma

Symptoms & Phenotypes for Large Cell Neuroendocrine Carcinoma

GenomeRNAi Phenotypes related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.9 EGFR
2 Decreased viability GR00055-A-2 9.9 EGFR
3 Decreased viability GR00173-A 9.9 PDGFRA
4 Decreased viability GR00221-A-1 9.9 ALK EGFR KIT NTRK2 PDGFRA
5 Decreased viability GR00221-A-2 9.9 NTRK2 NTRK3
6 Decreased viability GR00221-A-3 9.9 PDGFRA ERBB2
7 Decreased viability GR00221-A-4 9.9 ALK EGFR NTRK2 PDGFRA ERBB2 NTRK3
8 Decreased viability GR00249-S 9.9 ALK PDGFRA
9 Decreased viability GR00301-A 9.9 KIT
10 Decreased viability GR00402-S-2 9.9 PDGFRA
11 Decreased cell viability after pRB stimulation GR00230-A-1 8.65 NTRK2

MGI Mouse Phenotypes related to Large Cell Neuroendocrine Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 ALK ASCL1 CD274 DLL3 ENO2 ERBB2
2 growth/size/body region MP:0005378 10.31 ALK ASCL1 CHGA DLL3 EGFR ENO2
3 mortality/aging MP:0010768 10.28 ALK ASCL1 CD274 CHGA DLL3 EGFR
4 cellular MP:0005384 10.26 ASCL1 CD274 EGFR ENO2 ERBB2 KIT
5 nervous system MP:0003631 10.24 ALK ASCL1 CHGA DLL3 EGFR ENO2
6 endocrine/exocrine gland MP:0005379 10.16 ALK ASCL1 CHGA EGFR ERBB2 KIT
7 normal MP:0002873 10 ALK ASCL1 EGFR ERBB2 KIT NKX2-1
8 no phenotypic analysis MP:0003012 9.92 ASCL1 CD274 CHGA EGFR KIT NKX2-1
9 reproductive system MP:0005389 9.85 ALK CHGA DLL3 EGFR ERBB2 KIT
10 respiratory system MP:0005388 9.7 ALK ASCL1 EGFR ENO2 ERBB2 KIT
11 vision/eye MP:0005391 9.28 ALK ASCL1 DLL3 EGFR KIT NCAM1

Drugs & Therapeutics for Large Cell Neuroendocrine Carcinoma

Drugs for Large Cell Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Etoposide Approved Phase 2 33419-42-0 36462
3
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
4
Somatostatin Approved, Investigational Phase 1, Phase 2 51110-01-1, 38916-34-6 53481605
5
Ipilimumab Approved Phase 2 477202-00-9
6
nivolumab Approved Phase 2 946414-94-4
7 Antimitotic Agents Phase 2
8 Albumin-Bound Paclitaxel Phase 2
9 Tubulin Modulators Phase 2
10 Etoposide phosphate Phase 2
11 Antineoplastic Agents, Immunological Phase 2
12 Immunoglobulins Phase 2
13 Antibodies, Monoclonal Phase 2
14 Antibodies Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study Unknown status NCT02943798 Phase 2 etoposide plus carboplatin;Paclitaxel plus carboplatin
2 A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung Completed NCT02936323 Phase 1, Phase 2 PEN-221
3 A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas Recruiting NCT04079712 Phase 2 Cabozantinib S-malate
4 uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung Recruiting NCT02755675 Phase 2
5 A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma Terminated NCT02500914 Phase 1 SC-002
6 Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017) Completed NCT03305133
7 A Pilot Feasibility Study of Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma Recruiting NCT04452292
8 Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix Recruiting NCT04723095

Search NIH Clinical Center for Large Cell Neuroendocrine Carcinoma

Genetic Tests for Large Cell Neuroendocrine Carcinoma

Anatomical Context for Large Cell Neuroendocrine Carcinoma

MalaCards organs/tissues related to Large Cell Neuroendocrine Carcinoma:

40
Lung, Breast, Cervix, Colon, Thymus, Ovary, Thyroid

Publications for Large Cell Neuroendocrine Carcinoma

Articles related to Large Cell Neuroendocrine Carcinoma:

(show top 50) (show all 1051)
# Title Authors PMID Year
1
Esophageal large cell neuroendocrine carcinoma. 61
32505568 2021
2
Primary renal large cell neuroendocrine carcinoma with horseshoe kidney: A case report. 61
33568338 2021
3
Erratum: Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review. 61
33758667 2021
4
Challenges in Ki-67 assessments in pulmonary large-cell neuroendocrine carcinomas. 61
33025627 2021
5
Detection of Cauda Equine Syndrome With 18F-FDG PET/CT and Leptomeningeal Metastasis by 68Ga-DOTATATE in the Same Patient With Large Cell Neuroendocrine Carcinoma of Lung. 61
33661196 2021
6
High-grade Neuroendocrine Carcinomas of the Vulva: A Clinicopathologic Study of 16 Cases. 61
32826525 2021
7
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment. 61
33250511 2021
8
SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma. 61
33581550 2021
9
Recent advances and current controversies in lung neuroendocrine neoplasms✰. 61
33810912 2021
10
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. 61
33172976 2021
11
Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer? 61
33661698 2021
12
Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer. 61
33804482 2021
13
miR-31 Displays Subtype Specificity in Lung Cancer. 61
33558335 2021
14
A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes. 61
33609752 2021
15
Incarcerated sigmoid large-cell neuroendocrine carcinoma in an inguinal hernia. 61
33604019 2021
16
Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review. 61
33579331 2021
17
Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. 61
33639649 2021
18
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. 61
33722498 2021
19
Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review. 61
33414915 2021
20
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours. 61
33475525 2021
21
Primary Large Cell Neuroendocrine Carcinoma of the Parotid Gland. Report of a Rare Case. 61
33544384 2021
22
Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior : Description of a case and review of the pertinent literature. 61
33454836 2021
23
Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States. 61
33569294 2021
24
[Pregnancy-preserving and maternal-fetal management in a patient with rare large cell neuroendocrine carcinoma of the uterine cervix]. 61
33509747 2021
25
[A Case of Large Cell Neuroendocrine Carcinoma Metastatic to the Brain]. 61
33494068 2021
26
Ectopic insulin secretion by a large-cell neuroendocrine carcinoma of the cervix. 61
33505694 2021
27
Aggressive clinical course of large cell neuroendocrine carcinoma of the ampulla of Vater. 61
33629034 2021
28
Identification of novel transcription factor-microRNA-mRNA co-regulatory networks in pulmonary large-cell neuroendocrine carcinoma. 61
33569435 2021
29
Combined large cell neuroendocrine carcinoma and spindle cell carcinoma of the lung: Report of a rare entity presenting in fine needle aspiration. 61
32656908 2021
30
Primary large cell neuroendocrine carcinoma of the ovary: A rare entity. 61
33716217 2021
31
Morphologic and molecular classification of lung neuroendocrine neoplasms. 61
33474631 2021
32
Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study. 61
32097950 2021
33
Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity. 61
33197299 2021
34
Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience. 61
32335553 2021
35
Pure large cell neuroendocrine carcinoma of the gallbladder, is surgical relentlessness beneficial? A case report and literature review. 61
33425643 2021
36
Successfully managed combined pulmonary fibrosis and emphysema in a lung large cell neuroendocrine carcinoma patient treated with pembrolizumab. 61
33427390 2021
37
Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. 61
33514539 2021
38
[Comprehensive genomic profiling in large cell neuroendocrine lung cancer: the times they are a-changin'.] 61
33512365 2021
39
Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung. 61
33451319 2021
40
Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage. 61
33525370 2021
41
Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature. 61
33171403 2020
42
Neuroendocrine tumors of the lung: clinicopathological and molecular features. 61
32193632 2020
43
Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. 61
33017591 2020
44
Neuroendocrine Lung Cancer Mouse Models: An Overview. 61
33375066 2020
45
Hypokalaemia and peripheral oedema in a Cushingoid patient with metastatic prostate cancer. 61
33380539 2020
46
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. 61
33352665 2020
47
Primary pure large cell neuroendocrine carcinoma of the ovary: A rare case report and review of literature. 61
33285672 2020
48
[A Case of Large Cell Neuroendocrine Carcinoma of the Ampulla of Vater]. 61
33468974 2020
49
A case of colorectal large cell neuroendocrine carcinoma accompanied by disseminated peritoneal leiomyomatosis. 61
33296060 2020
50
Pulmonary large cell neuroendocrine carcinoma (LCNEC) with confirmed liver metastases negative on 18F-FDG and 68Ga-DOTATATE PET. 61
33117470 2020

Variations for Large Cell Neuroendocrine Carcinoma

Expression for Large Cell Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Large Cell Neuroendocrine Carcinoma.

Pathways for Large Cell Neuroendocrine Carcinoma

Pathways related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 PDGFRA NEUROD1 NCAM1 KRT7 KRT20 KRT18
2
Show member pathways
13.22 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
3
Show member pathways
13.17 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
4
Show member pathways
12.94 PDGFRA NTRK3 NTRK2 KIT EGFR ALK
5
Show member pathways
12.78 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
6 12.71 PDGFRA KIT ERBB2 EGFR DLL3 ALK
7 12.66 PDGFRA NTRK2 KIT ERBB2 EGFR
8
Show member pathways
12.57 PDGFRA ERBB2 EGFR DLL3 ALK
9 12.4 SYP NTRK3 NTRK2 NKX2-1 NEUROD1 NCAM1
10
Show member pathways
12.31 PDGFRA NTRK3 NTRK2 ERBB2 EGFR
11 12.23 PDGFRA NTRK3 NTRK2 ERBB2 EGFR
12
Show member pathways
12.21 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
13
Show member pathways
12.16 PDGFRA NTRK3 NTRK2 KIT EGFR
14
Show member pathways
12.11 PDGFRA NTRK3 NTRK2 ERBB2 EGFR
15 11.62 PDGFRA NTRK3 NTRK2 ERBB2 EGFR
16 11.6 PDGFRA NTRK2 KIT ERBB2 EGFR ALK
17 11.55 SYP PDGFRA NEUROD1 NCAM1 ASCL1
18 11.46 PDGFRA NCAM1 KIT
19 11.4 PDGFRA NTRK3 KIT ERBB2 EGFR
20 10.88 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
21 10.67 PDGFRA NTRK3 NTRK2 ERBB2 EGFR

GO Terms for Large Cell Neuroendocrine Carcinoma

Cellular components related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.63 SYP NTRK2 KRT18 ERBB2 EGFR CHGA
2 external side of plasma membrane GO:0009897 9.35 PDGFRA NCAM1 KRT18 KIT CD274
3 receptor complex GO:0043235 9.17 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR

Biological processes related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.14 NTRK3 NTRK2 NKX2-1 NEUROD1 EGFR DLL3
2 positive regulation of gene expression GO:0010628 10.06 NTRK3 NTRK2 NKX2-1 KIT ERBB2
3 positive regulation of cell proliferation GO:0008284 10.05 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
4 nervous system development GO:0007399 10.03 NTRK3 NTRK2 NEUROD1 ERBB2 ASCL1 ALK
5 phosphorylation GO:0016310 10.02 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
6 multicellular organism development GO:0007275 10.02 PDGFRA NTRK3 NTRK2 NEUROD1 KIT ERBB2
7 protein phosphorylation GO:0006468 10 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 PDGFRA NTRK3 NTRK2 EGFR
9 positive regulation of protein phosphorylation GO:0001934 9.94 NTRK3 NTRK2 ERBB2 EGFR
10 MAPK cascade GO:0000165 9.93 PDGFRA NCAM1 KIT ERBB2 EGFR
11 positive regulation of protein kinase B signaling GO:0051897 9.92 PDGFRA KIT ERBB2 EGFR
12 neuron differentiation GO:0030182 9.91 NTRK2 NEUROD1 ERBB2 ASCL1
13 positive regulation of cell migration GO:0030335 9.88 VIL1 PDGFRA NTRK3 KIT EGFR CD274
14 positive regulation of MAPK cascade GO:0043410 9.85 NTRK3 NTRK2 KIT ERBB2
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 NTRK3 NTRK2 EGFR
16 neuron migration GO:0001764 9.83 NTRK3 NTRK2 NKX2-1 ASCL1
17 neuron development GO:0048666 9.81 NEUROD1 ASCL1 ALK
18 positive regulation of MAP kinase activity GO:0043406 9.8 KIT ERBB2 EGFR
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 PDGFRA NTRK3 NTRK2 KIT
20 cellular response to epidermal growth factor stimulus GO:0071364 9.77 VIL1 ERBB2 EGFR
21 protein autophosphorylation GO:0046777 9.73 PDGFRA NTRK2 KIT ERBB2 EGFR ALK
22 peptidyl-tyrosine phosphorylation GO:0018108 9.7 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
23 oligodendrocyte differentiation GO:0048709 9.67 NTRK2 NKX2-1 ERBB2 ASCL1
24 tongue development GO:0043586 9.65 KIT EGFR
25 Leydig cell differentiation GO:0033327 9.65 PDGFRA NKX2-1
26 forebrain neuron differentiation GO:0021879 9.65 NKX2-1 ASCL1
27 negative regulation of ERBB signaling pathway GO:1901185 9.62 ERBB2 EGFR
28 mast cell chemotaxis GO:0002551 9.61 KIT CHGA
29 positive regulation of phospholipase C activity GO:0010863 9.61 PDGFRA NTRK3 KIT
30 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.58 NKX2-1 ASCL1
31 neurotrophin signaling pathway GO:0038179 9.57 NTRK3 NTRK2
32 mast cell cytokine production GO:0032762 9.51 KIT CHGA
33 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.5 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
34 positive regulation of kinase activity GO:0033674 9.17 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR

Molecular functions related to Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.8 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
2 protein kinase activity GO:0004672 9.7 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
3 protein tyrosine kinase activity GO:0004713 9.5 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR
4 neurotrophin binding GO:0043121 9.37 NTRK3 NTRK2
5 neurotrophin receptor activity GO:0005030 9.32 NTRK3 NTRK2
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.17 PDGFRA NTRK3 NTRK2 KIT ERBB2 EGFR

Sources for Large Cell Neuroendocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....